Literature DB >> 3872878

The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans.

A G Palestine, F Roberge, B L Charous, H C Lane, A S Fauci, R B Nussenblatt.   

Abstract

Eleven patients with chronic uveitis treated with Cyclosporine were immunized with keyhole limpet hemocyanin (KLH) and tetanus toxoid. Delayed cutaneous hypersensitivity responses, lymphocyte blastogenic responses, and antibody production were compared with those of similarly immunized control individuals. A significant decrease in delayed cutaneous hypersensitivity (P less than 0.001 for KLH and P less than 0.01 for tetanus toxoid) was observed. No significant differences in blastogenic or antibody responses were noted. These findings demonstrate that the majority of the Cyclosporine-treated patients had intact T cell-dependent antigen responses as measured by both proliferative response and antibody production to primary and secondary antigenic challenges but that other immune functions such as delayed cutaneous hypersensitivity are affected by therapeutic doses of systemic Cyclosporine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872878     DOI: 10.1007/bf00915009

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

1.  Cyclosporin for Crohn's disease.

Authors:  M C Allison; R E Pounder
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

2.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

3.  Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation.

Authors:  D J Volkman; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

4.  Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell.

Authors:  G A Dos Reis; E M Shevach
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Cyclosporin A--a pre-recruitment action in the cutaneous response?

Authors:  V M Rumjanek; L A Smith; J Morley
Journal:  Immunol Lett       Date:  1983-02       Impact factor: 3.685

6.  Treatment of intraocular inflammatory disease with cyclosporin A.

Authors:  R B Nussenblatt; A G Palestine; A H Rook; I Scher; W B Wacker; I Gery
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

7.  Selective effects of cyclosporin A on functional B cell subsets in the mouse.

Authors:  A Kunkl; G G Klaus
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

8.  Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats.

Authors:  R B Nussenblatt; M M Rodrigues; W B Wacker; S J Cevario; M C Salinas-Carmona; I Gery
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

9.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

10.  In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements.

Authors:  H C Lane; D J Volkman; G Whalen; A S Fauci
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  13 in total

1.  Evidence that calcineurin is rate-limiting for primary human lymphocyte activation.

Authors:  T D Batiuk; L Kung; P F Halloran
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.

Authors:  Alexandra Belson; Tim Schmidt; Disala Fernando; Kelly Hardes; Nicola Scott; Sara Brett; Deborah Clark; João Joaquim Oliveira; Bill Davis; Simon McHugh; John Stone
Journal:  Inflamm Res       Date:  2016-03-11       Impact factor: 4.575

3.  Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.

Authors:  C Boitard; G Feutren; L Castano; M Debray-Sachs; R Assan; J Hors; J F Bach
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  Precipitation of experimental autoallergic uveoretinitis by cyclosporin A withdrawal: an experimental model of uveitis relapse.

Authors:  E G Atkinson; W J Dinning; E Kasp; E M Graham; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

5.  Does autoimmunity to S-antigen play a role in Fuchs' heterochromic cyclitis?

Authors:  E La Hey; L Broersma; R van der Gaag; G S Baarsma; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

6.  Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients.

Authors:  V L Calder; A S Bellamy; S Owen; C Lewis; P Rudge; A N Davison; M Feldmann
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

7.  Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?

Authors:  Reinhart Speeckaert; Jo Lambert; Luis Puig; Marijn Speeckaert; Hilde Lapeere; Sofie De Schepper; Nanja van Geel
Journal:  Drugs R D       Date:  2021-06-09

8.  Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey.

Authors:  Caroline Bouchez; Fréderic Gervais; Renaud Fleurance; Bernard Palate; Jean-Jacques Legrand; Jacques Descotes
Journal:  J Toxicol Pathol       Date:  2012-06       Impact factor: 1.628

Review 9.  Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.

Authors:  Oriana Simonetti; Giulia Radi; Elisa Molinelli; Giulio Rizzetto; Federico Diotallevi; Annamaria Offidani
Journal:  Hum Vaccin Immunother       Date:  2021-06-25       Impact factor: 4.526

10.  The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation.

Authors:  D Weissman; T D Barker; A S Fauci
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.